CFF Aids Development of NO-based Therapy, BIOC51, for Resistant Bacteria, Vast Therapeutics Says

CFF Aids Development of NO-based Therapy, BIOC51, for Resistant Bacteria, Vast Therapeutics Says Dec 19, 2018 07:00 am | Santiago Gisler Vast Therapeutics announced that it received funding from the Cystic Fibrosis Foundation (CFF) to support further development of BIOC51, the company’s investigative treatment for antibiotic-resistant bacteria, including Pseudomonas aeruginosa, that is often the cause of lung infections in cystic fibrosis (CF) patients. P. aeruginosa infections set in when mucus accumulation clogs the airways, and the bacteria subsequently form […] The post CFF Aids Development of NO-based Therapy, BIOC51, for Resistant Bacteria, Vast Therapeutics Says appeared first on Cystic Fibrosis News Today.

Read More